Skip to main content

Clinical Trials Using Polatuzumab Vedotin

Review the clinical trials studying polatuzumab vedotin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-23 of 23

Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 85 locations
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status: Active
Location: 30 locations
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Status: Active
Location: 14 locations
Zanubrutinib in Combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone and High-Dose Methotrexate for the Treatment of Patients with Large B-cell Lymphoma with Central Nervous System Involvement
Status: Active
Location: 8 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 7 locations
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 7 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
Glofitamab plus Polatuzumab-R-CHP for the Treatment of High-Risk Diffuse Large B-Cell Lymphoma
Status: Active
Location: 4 locations
Glofitamab and Obinutuzumab with or without Polatuzumab Vedotin, Pirtobrutinib or Atezolizumab for the Treatment Richter's Transformation
Status: Active
Location: 4 locations
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
Status: Active
Location: 3 locations
Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Status: Active
Location: 2 locations
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Status: Active
Location: 3 locations
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Status: Active
Location: 2 locations
Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for the Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Genetically Engineered Cells (Anti-CD19 CAR-T Cell Therapy) and Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Refractory/Relapsed Aggressive Non-Hodgkin Lymphoma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Polatuzumab Vedotin and Rituximab With or Without Chemotherapy for the Treatment of Post-Transplant Lymphoproliferative Disorder
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Tafasitamab, Retifanlimab, and Rituximab in Combination with Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Temporarily Closed to Accrual
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Real-Time Circulating Tumor Deoxyribonucleic Acid Sequencing to Guide Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma, SHORTEN-ctDNA Trial
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York